Siegfried Holding stock
SFZN.SWSIXSiegfried Holding AG, HealthcareISIN CH1429326825
55Score 55 out of 100, Neutral
Price and trend
42 / 100
Price history
−6.7% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 7.1% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 44).
The price is 29% below its 52-week high. Largest decline in 20 years: 73% (July 2007 to March 2009).
Chart figures for advanced users
- SMA 50$86.30
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$92.38
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)44
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$80.61
- The lowest closing price of the last twelve months.
- Resistance$120.50
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Siegfried Holding AG belongs to the Drug Manufacturers (Specialty & Generic) industry (Switzerland) and, with a market value of $3.76B, is number 45 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $1.6B (up 2.6% year on year) and earnings of $203.23M (up 5.4%).
- For fiscal 2026, analysts expect on average revenue of $1.71B (up 7%) and adjusted earnings per share of $4.88 (up 9.7%).
Show more
- MEQIRI Score 55 out of 100 (Neutral): rank 337 of 714 in Healthcare, median 53.
- The P/E is 18.3 (Drug Manufacturers (Specialty & Generic) median 19.3, own median of recent years 3.4).
- Our model puts fair value at $127.54, with the price 33% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 58
Weaknesses
- Earnings per share fallingDown 23.5% a year since 2020.Growth 29
- Negative free cash flowFree cash flow −$21.98M over the last 12 months.Fundamentals 58
Its standout strengths are stability and valuation, while technical analysis and growth hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
Valuation
Valuation signal
Possible value trapClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $98.11 and expensive above $182.20 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $164.17 (cash-flow model) and $90.91 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 5.6%. At 6.6% the fair value would be $111.23, at 4.6% it would be $152.27.
Possible value trap: looks cheap, but weak growth.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 3.6% on the twelve months before. Revenue has grown solidly since 2006, at about 8% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 27%, operating 16%, net 13%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 19 Feb 2027in 99 days
- Last reported
- 21 Aug 2026EPS reported $1.87 (expected $1.90)in line with expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $4.88−0.6%
- Revenue
- $1.71B−0.1%
- Earnings per share
- $5.56−1.4%
- Revenue
- $1.87B−0.7%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −2.9%Guidance confirmed: high single-digit growth in local currencies and EBITDA margin above 23%.
“We are confident to confirm our guidance, high single-digit growth in local currencies and an EBITDA margin above 23%.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 21 Aug 2026 (fiscal Q2 2026), read by AI.
What happened at Siegfried Holding
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 55
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Sumitomo Pharma4506.T $5.45B57
- Ipca LaboratoriesIPCALAB.NS $5.25B70
- Shenzhen Salubris Pharmaceuticals002294.SZ $5.03B53
- Laboratorios Farmaceuticos RoviROVI.MC $4.02B82
- Bausch Health CompaniesBHC $3.13B61
- Regencell Bioscience HoldingsRGC $2.68B31
- HUTCHMED (China)HCM $2.63B45
- AlmirallALM.MC $2.61B45
ETFs that hold Siegfried Holding
Held by 24 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares STOXX Europe Small 200 UCITS ETF (DE)EXSE | 0.44% | 0.20% | €632.25M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.35% | 0.40% | €1.49B |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.24% | 0.23% | €319.31M |
Show 5 more
| Ossiam STOXX Europe 600 Equal Weight NR UCITS ETFOSX6 | 0.21% | 0.30% | €215.59M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.21% | 0.30% | €3.43B |
| iShares STOXX Europe 600 Health Care UCITS ETF (DE)EXV4 | 0.17% | 0.46% | €729.65M |
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.11% | 0.30% | €810.11M |
| Avantis Global Small Cap Value UCITS ETFAVWS | 0.08% | 0.39% | €1.47B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = CHF 0.8299)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.